Newron Pharmaceuticals S.p.A.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Newron Pharmaceuticals S.p.A.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.
The ABV 8 fund will invest $15m to $30m per company across the range from start-ups to development-stage companies.
Days after buying Kymab, Sanofi partners with Israel’s Biond on IO candidate targeting ILT2. Gilead again tackles functional cure of hepatitis B in alliance with Vir.
- Other Names / Subsidiaries
- NeuroNova AB
- Newron Pharmaceuticals SpA